2015-09-11 14:44:56 UTC
Sept. 14, 2015
What FDA approval of the ReShape and ORBERA devices for obesity means to GIs.
Although the gut is an intuitive therapeutic target for obesity, gastroenterologists have played a surprisingly small role in the management of this major health disorder. With the recent FDA approvals of ReShape and ORBERA obesity devices, GIs now have an invitation to join the party … with balloons.
In a guest blog post on Healio Gastroenterology, Pankaj Jay Pasricha, MD, executive committee member and past chair of the AGA Center for GI Innovation and Technology, explains how GIs can play a role in obesity management. Specifically, Dr. Pasricha discusses the potential revenue stream from obesity management and the need for a well-thought-out and multi-disciplinary approach.
Read Dr. Pasricha’s commentary and stay tuned for additional guidance from AGA and the AGA Center for GI Innovation and Technology on how GIs can realistically implement these procedures into practice.